Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38
Insiders who bought US$126.3k worth of Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) stock at an average buy price of US$7.84 over the last year may be disappointed by the recent 12% decrease in the stock. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$86.6k which is not ideal.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
The Last 12 Months Of Insider Transactions At Corbus Pharmaceuticals Holdings
Over the last year, we can see that the biggest insider purchase was by Chief Business Officer Nishant Saxena for US$101k worth of shares, at about US$7.58 per share. That means that an insider was happy to buy shares at above the current price of US$5.38. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Nishant Saxena.
Nishant Saxena bought 16.10k shares over the last 12 months at an average price of US$7.84. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
View our latest analysis for Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Does Corbus Pharmaceuticals Holdings Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data isn't picking up on much insider ownership at Corbus Pharmaceuticals Holdings, though insiders do hold about US$506k worth of shares. This level of insider ownership is notably low, and not very encouraging.
What Might The Insider Transactions At Corbus Pharmaceuticals Holdings Tell Us?
Insider purchases may have been minimal, in the last three months, but there was no selling at all. The net investment is not enough to encourage us much. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Corbus Pharmaceuticals Holdings stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 4 warning signs for Corbus Pharmaceuticals Holdings (3 make us uncomfortable!) and we strongly recommend you look at them before investing.
Of course Corbus Pharmaceuticals Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.